P. Munda

Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity.

M. Trauner, G. Prager, J. Stift, 2021, Hepatobiliary surgery and nutrition.

Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease

C. Datz, J. Hampe, A. Canbay, 2021, Hepatology International.

Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders

M. Pollheimer, M. Trauner, G. Paumgartner, 2015, Digestive Diseases.

Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study

M. Trauner, P. Ferenci, H. Holzmann, 2022, Alimentary pharmacology & therapeutics.

Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease

R. Stauber, M. Trauner, V. Stadlbauer, 2019, United European gastroenterology journal.

Prevalence of anti‐Hepatitis E antibodies and impact on disease severity in non‐alcoholic fatty liver disease

M. Trauner, F. Wrba, E. Halilbasic, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease

M. Wolzt, M. Trauner, T. Stojaković, 2020, Wiener klinische Wochenschrift.

Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH

M. Trauner, E. Halilbasic, H. Hofer, 2015, Digestive Diseases.

Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders

M. Pollheimer, M. Trauner, G. Paumgartner, 2015, Digestive Diseases.